Mirum Pharmaceuticals ((MIRM)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Mirum Pharmaceuticals is conducting a study titled ‘A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Biliary Cholangitis.’ The study aims to assess the effectiveness and safety of the investigational drug volixibat for treating itching associated with Primary Biliary Cholangitis (PBC) and its potential impact on disease progression.
The intervention being tested is volixibat, an oral Ileal Bile Acid Transporter (IBAT) inhibitor, administered in capsule form twice daily. The study includes different dosages of volixibat and a placebo for comparison.
This interventional study is randomized and follows a parallel assignment model with double masking for participants and investigators. Its primary purpose is treatment-focused, aiming to provide insights into volixibat’s efficacy and safety.
The study began on September 22, 2021, and is currently recruiting participants. The last update was submitted on August 21, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
The outcome of this study could significantly influence Mirum Pharmaceuticals’ stock performance and investor sentiment, especially if volixibat proves effective. It could also impact the competitive landscape in treatments for PBC-related pruritus.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.